Q3 beat; promising growth across the key offerings
30/10/24 -"bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance remained unchanged, investors rejoiced at the ..."
Pages
61
Language
English
Published on
30/10/24
You may also be interested by these reports :
31/10/24
Amplifon’s Q3 profitability missed the market’s expectations. The mid-single-digit organic sales growth was driven by growth across all regions. ...
30/10/24
bioMerieux’s Q3 organic sales were a beat. The double-digit growth was driven by a healthy contribution from both segments. While the 2024 guidance ...
30/10/24
Clariane’s turnover growth continued to be driven by increases in both volume and pricing across all the business segments and regions. The group ...
30/10/24
Drägerwerk’s Q3 24 numbers were exactly in line with the prelims. Sales were down, with declines across both segments. However, with a book-to-bill ...